RTI INTERNATIONAL

RTI Health Solutions and Global Pricing Innovations announce strategic collaboration to enhance decision-making and support for clients, offering end-to-end integrated solutions across the drug development life cycle.

A study identified new genes linked to alcoholism (AUD) in brain regions relevant to addiction, revealing 176 differentially expressed genes (DEGs) and potential drug targets for AUD treatment.

RTI International and Codetta Bio collaborate to accelerate healthcare innovation, leveraging Codetta’s multi-omics technology for disease and treatment research.

A clinical trial led by Keith McCrae, M.D., at Cleveland Clinic demonstrated that pomalidomide, a cancer drug, is safe and effective for treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder. The trial, supported by the National Institutes of Health, was stopped early due to successful findings and published in the New England Journal of Medicine. Pomalidomide significantly reduced nosebleed severity, required fewer blood transfusions, and improved quality of life for HHT patients.

The article profiles various professionals in health and statistics, including John R. Lumpkin, M.D., M.P.H., Mollyann Brodie, Ph.D., Kennon R. Copeland, Ph.D., Tara Das, Ph.D., M.P.H., M.L.I.S., Scott H. Holan, Ph.D., V. Joseph Hotz, Ph.D., Bradley Malin, Ph.D., Sally C. Morton, Ph.D., Lucila Ohno-Machado, M.D., M.B.A., Ph.D., Andy Peytchev, Ph.D., C. Matthew Snipp, Ph.D., Kelly Hoover Thompson, J.D., and David R. Williams, Ph.D., detailing their roles, achievements, and contributions to their respective fields.